10

A co-precipitate comprising cefuroxime axetil and a water-soluble excipient.

- A co-precipitate as in claim 1 comprising from about 40% to about 98% 2. by weight cefuroxime axetil and from/about 2% to about 60% by weight water- soluble excipient.
- A co-precipitate as in claim 1 comprising from about 75% to about 95% 3. by weight cefuroxime axetil and from about 5% to about 25% by weight water-soluble excipient.
- A co-precipitate as in claim 1 comprising about 90% by weight cefuroxime 4. axetil and about 10% by weight water-soluble excipient.
- A co-precipitate as in any of claims 1 to 4 wherein the water-soluble 5. excipient is selected from the group consisting of povidone, hydroxy propyl cellulose, methycellulose, lactose, mannitol and sorbitol.
- A process of production of a co-precipitate of any of claims 1-to 5 which 6. comprises:
  - dissolving the cefuroxime axetil and water-soluble excipient in a solvent or a mixture of solvents; and evaporating the solvent or solvents.
- A proces's as in claim 6 wherein acetone is used as solvent. 7.
- A process as in claim 6 wherein the solvent or solvents are evaporated 30 by spray-drying.

**19465534 021400** 

25

- A pharmaceutical tablet comprising a co-precipitate according to any-of-9. claims-1-to-5.
- 5 A pharmaceutical tablet as in claim 9 further comprising a disintegrant. 10.
  - A pharmaceutical tablet as in claim 10 wherein the disintegrant is a water-11. insoluble cross-linked polymer.
- 10 A pharmaceutical tablet as in claim 10 wherein the disintegrant is 12. selected from the group consisting of croscarmellose sodium, sodium COFOLSOR DELFOS starch glycolate and crospovidone.
  - A pharmaceutical tablet as in claim 10 further comprising a lubricant. 13.
  - A pharmaceutical tablet as in claim 13 wherein the lubricant is stearic acid 14. or a metallic stearate.